STVN STEVANATO GRP SPA

Stevanato Group to Report Second Quarter Financial Results on August 19

PIOMBINO DESE, Italy--(BUSINESS WIRE)--

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the second quarter of fiscal year 2021 on Thursday, August 19, 2021.

The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 CET) on August 19, 2021. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, please visit the “Financial Results” page, under the Company's Investor Relations section of its website.

To participate on the call please dial

United States: 1 855 979 6654

Italy: 800 684 570

International: 9

Access Code: 627926

Preregistration:

Listeners are encouraged to preregister for the call via the following link: , whereupon you will be provided with a unique dial-in number and access code.

For Participants that do not preregister:

A live broadcast of the conference call will also be available online at the following link: (access code 627926).

Replay:

An online archive of the broadcast will be available at the website shortly after the live call and will be available through Thursday 2 September 2021. The recording will be accessible via the following link: (access code 776594).

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

For more information, please visit

EN
11/08/2021

Underlying

STVNSTEVANATO GRP SPA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STEVANATO GRP SPA

 PRESS RELEASE
Free
STVN STEVANATO GRP S...

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual ...

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Healthcare Forum taking place from Tuesday, March 18 to Wednesday, March 19, 2025. The Company will present on Tuesday, March 18, at 3.00 p.m. (ET). A live webcast will be available on the Company’s website at under the "Investors" section. A replay of the webcast will be available for approximately 90 days after t...

March 11, 2025 1 EN
 PRESS RELEASE
Free
STVN STEVANATO GRP S...

Stevanato Group Reports Record Revenue of €1,104 Million for Fiscal Ye...

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024. Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year period) Revenue for the fourth quarter of 2024 increased 3% to €330.6 million, and high-value solutions represented 40% of total revenue, in line with Company expectations. For the fourth quarter, diluted ear...

March 6, 2025 1 EN
 PRESS RELEASE
Free
STVN STEVANATO GRP S...

Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financia...

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation that...

February 24, 2025 1 EN
Thomas J. Schiessle
  • Thomas J. Schiessle
EUR 290.00
GLW CORNING INC
GXI GERRESHEIMER AG ... (+3)

Sondierungsgespräche mit Private Equity – GXI in Transition

Mit Private Equity Investoren hätten lt. CN v 07.02.25 auf informeller und unverbindlicher Basis ihr „Interesse an einem möglichen öffentlichen Übernahmeangebot bekundet“. Interesse von Finanzinvestoren gab es bereits in der Vergangenheit. GXI ist in einer Übergangsphase, zumal die Bormioli-Integration andauert. Seit der Gewinnwarnung im 09/24 hatte sich der Aktienkurs fast halbiert.

GLW CORNING INC
GXI GERRESHEIMER AG
STVN STEVANATO GRP SPA
02/10/25 February 10, 2025 4 DE
Thomas J. Schiessle
  • Thomas J. Schiessle
EUR 290.00
GLW CORNING INC
GXI GERRESHEIMER AG ... (+3)

Exploratory talks with private equity – GXI in transition

According to CN 07.02.25, private equity investors have expressed ‘interest in a potential public takeover offer’ on an informal and non-binding basis. GXI is in a transition phase, especially as the Bormioli integration is ongoing. There has been interest from financial investors in the past. Since the profit warning on 09/24, the share price has almost halved.

GLW CORNING INC
GXI GERRESHEIMER AG
STVN STEVANATO GRP SPA
02/10/25 February 10, 2025 4 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch